By: IPP Bureau
Last updated : February 24, 2026 3:36 pm
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Eris Lifesciences Limited announced a strategic partnership with Natco Pharma Limited to commercialise Semaglutide in India. This collaboration leverages Natco’s manufacturing capabilities and Eris’s established commercial network to target the high-growth Type 2 diabetes and weight management markets.
Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction. With India witnessing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment.
This collaboration builds on both companies’ complementary strengths: Eris’s robust commercial and diabetes franchise presence, and Natco’s manufacturing and regulatory prowess in complex formulations.
Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market, paving the way for a launch expected in March 2026.
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape.
Amit Bakshi, Chairman & Managing Director, Eris Lifesciences Ltd, said: “Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies, we believe Eris is well positioned to drive rapid adoption and enhance patient access in India.”
He further added that Eris has been proactively preparing its commercial strategy to participate meaningfully in the GLP-1 opportunity and views this partnership as a long-term value driver for the company.